PTMAP6

Across TCGA pan-cancer cohorts, PTMAP6 RNA is linked to patient survival in 11 of 34 cancer types, making it the most broadly survival-associated PTMAP6 data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher PTMAP6 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated PTMAP6 expression acts as an unfavorable survival marker, although some lineages such as BRCA and LAML show a favorable association.

STAD, BRCA, and UVM are the cancer types where PTMAP6 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Tertile	II,III,IV	0.542	0.666	.022	54	view →
BRCA	OS	Tertile	All	0.673	0.560	.004	51	view →
UVM	DFS	Tertile	III,IV	0.079	0.674	.020	36	view →
ESCA	DFS	Tertile	II,III,IV	0.384	0.580	.003	34	view →
LUAD	OS	Tertile	II,III,IV	0.534	0.762	.012	24	view →
UCEC	OS	Tertile	All	0.791	0.883	.011	24	view →
LAML	DFS	Quartile	All	0.696	0.519	.027	22	view →
MESO	OS	Tertile	III,IV	0.276	0.583	.034	9	view →
BLCA	OS	Tertile	All	1.000	0.359	.049	6	view →
LGG	DFS	Tertile	All	0.531	0.829	.015	3	view →
LUSC	DFS	Tertile	All	0.215	0.413	.025	3	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

PTMAP6–STAD (DFS)

Open the STAD breakdown →